UNLV’s New Research on HIV
Researchers from the University of Nevada Las Vegas have begun working on new research on HIV, human immunodeficiency virus, by finding ways to stop the virus from infecting human cells.
UNLV has already earned several financial grants for the research, including one from the National Institutes of Health.
The researchers are looking at genetic codes called minimotifs that direct cellular function. Their goal is to understand how the codes can help cells fight off HIV by blocking the virus from interacting with the cells.
“We chose HIV as our model system because we know viruses depend solely on cells to live,” said Kiran Mathew, a researcher at UNLV, in an interview with the Las Vegas Review Journal. “It’s a great model system we can use to test out the effects of (the codes) in the cell.”
According to the U.S. Centers for Disease Control and Prevention, about 1.2 million Americans were infected with HIV as of 2012, with roughly 50,000 new cases each year.
By the end of 2014, close to 37 million people were living with HIV/AIDS worldwide and about 15 million people living with HIV were receiving antiretroviral therapy. The World Health Organization cites sub-Saharan Africa as the most affected region by HIV/AIDS globally with 26 million people infected in 2014. The region also accounts for almost 70 percent of the global total of new HIV infections.
There is currently no cure for HIV. The Food and Drug Administration has approved more than 25 antiretroviral drugs to help fight infections and improve quality of life for patients. With successful treatment, HIV infection can become a chronic, manageable disease. But therapy must be life long and there are limitations to diagnosis, treatment and care in geographical areas that are most heavily affected.
The promising new research coming out of UNLV might help develop new HIV drugs, code for other diseases and make personalized drugs specific for a patient’s genetic makeup. But first the findings must be published and patented before pharmaceutical companies could begin the process of bringing it to market where patients can benefit.
– Megan Ivy
Sources: Review Journal, CDC, WHO